	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	201.73	178.89	199.08	12.8%	1.3%
Operating Profit Qtr	29.00	18.36	19.48	58.0%	48.9%
Net Profit Qtr	21.00	19.60	10.51	7.1%	99.8%
Earning Per Share Adjusted latest Qtr	15.71	14.66	7.86	7.2%	99.9%

* Consolidated data

Detailed Results

Venus Remedies Ltd.

26 May 2025

428.60

-0.30%

Board Meeting

Venus Remedies Ltd - 526953 - Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2025.

BSE India

AS per enclosed pdf.

pdf

Venus Remedies Ltd.

22 May 2025

428.60

-0.30%

Company Update

Venus Remedies Ltd - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence.

pdf

Venus Remedies Ltd.

21 May 2025

428.60

-0.30%

Company Update

Venus Remedies Ltd - 526953 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Annual Secretarial Compliance report for the period ended on 31st Match 2025.

pdf

Venus Remedies Ltd.

17 May 2025

428.60

-0.30%

Board Meeting

Venus Remedies Ltd - 526953 - Board Meeting Intimation for The Meeting Of Board Of Directors …

BSE India

Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 26th May 2025 inter alia: 1. To consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March 2025. 2. Any other business with the permission of Chair.

pdf

Venus Remedies Ltd.

22 Apr 2025

428.60

-0.30%

Corp. Note

Venus Remedies Ltd - 526953 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyVenus Remedies Ltd 2CIN NO.L24232CH1989PLC009705 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Neha Designation: Company Secretary and Compliance Officer EmailId: complianceofficer@venusremedies.com Name of the Chief Financial Officer: Pawan Chaudhary Designation: CFO EmailId: corpsec@venusremedies.com Date: 22/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Venus Remedies Ltd. worth buying?

66 Votes:

Buy 74.24%

Sell 16.67%

Hold 9.09%